Companies Palvella Therapeutics, Inc
Palvella Therapeutics (PIRS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Palvella Therapeutics, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,404,904FY2025
CEO total pay was $3,404,904 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $575,000 · bonus $0 · stock awards $0 · option awards $2,469,886
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Wesley Kaupinen | $575,000 | $0 | $0 | $2,469,886 | $359,375 | $0 | $643 | $3,404,904 |
| President and Chief Executive Officer | ||||||||
| Kathleen Goin | 481,300 | 0 | 0 | 1,306,017 | 192,520 | 0 | 0 | 1,979,837 |
| Chief Operating Officer | ||||||||
| Matthew Korenberg | 475,300 | 0 | 0 | 1,306,017 | 190,120 | 0 | 0 | 1,971,437 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Wesley Kaupinen | $3,404,904 | — | — | — |
| Kathleen Goin | 1,979,837 | — | — | — |
| Matthew Korenberg | 1,971,437 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company provides base salary as a fixed source of income to attract and retain named executive officers, supplemented by annual performance-based cash bonuses and equity awards to align executive interests with stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Wesley Kaupinen | Option | 6,252 | 9.79 | — |
| Kathleen Goin | Option | 16,756 | 7.53 | — |
| Kathleen Goin | Option | 20,883 | 13.6 | — |
| Kathleen Goin | Option | 28,055 | 9.79 | — |
| Wesley Kaupinen | Option | 45,821 | 7.53 | — |
| Kathleen Goin | Option | 102,072 | 14.76 | — |
| Matthew Korenberg | Option | 102,072 | 14.76 | — |
| Matthew Korenberg | Option | 118,363 | 13.6 | — |
| Wesley Kaupinen | Option | 193,033 | 14.76 | — |
| Wesley Kaupinen | Option | 313,355 | 13.6 | — |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Peer group, and who names Palvella Therapeutics as a peer
Companies that benchmark against PIRS
No companies currently name PIRS as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Palvella Therapeutics, Inc | 2025 | Wesley Kaupinen | $575,000 | $0 | $2,469,886 | $359,375 | $3,404,904 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 10,008,180 | 160,717 | 7,157 | 98.42% | Passed |
| 2025 | 2025-06-10 | 6,550,393 | 61,078 | 36,866 | 99.08% | Passed |
| 2024 | 2024-12-02 | 604,490 | 6,678 | 634 | 98.91% | Passed |
| 2023 | 2023-06-21 | 17,227,404 | 2,828,509 | 5,556,466 | 85.9% | Passed |
| 2022 | 2022-06-22 | 30,353,634 | 1,565,728 | 390,087 | 95.09% | Passed |
| 2021 | 2021-06-25 | 26,115,252 | 2,718,810 | 3,646,312 | 90.57% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 98.42%a |
| 2025 | 2025-06-10 | 99.08%b |
| 2024 | 2024-12-02 | 98.91%c |
a. Approved under the standard stated in the filing — “PROPOSAL 3 : Approval, on an advisory basis, of the compensation of our named executive officers -- Majority of the votes properly cast | Abstentions: Abstentions and broker non-votes will have no effect on the outcome of the proposal”.
b. Approved under the standard stated in the filing — “PROPOSAL 3: Advisory vote to approve, on an advisory basis, the compensation of the our named executive officers -- Majority of the votes properly cast | Abstentions: Abstentions and broker non-votes will have no effect on the outcome of the proposal”.
c. Approved under the standard stated in the filing — “If a broker does not exercise this authority, such broker non-votes, as well as abstentions, will be counted as present for purposes of determining the presence of a quorum, but will have no effect on the results of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (7 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Wesley Kaupinen. DEF 14A, filed 2026-04-30. Section “SUMMARY COMPENSATION TABLE” · page 27. As printed: 3,404,904. View filing ↗
- Section 01, Kathleen Goin. DEF 14A, filed 2026-04-30. Section “SUMMARY COMPENSATION TABLE” · page 27. As printed: 1,979,837. View filing ↗
- Section 01, Matthew Korenberg. DEF 14A, filed 2026-04-30. Section “SUMMARY COMPENSATION TABLE” · page 27. As printed: 1,971,437. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-16. Item 5.07 · say-on-pay result. As reported: 98.42% (votes for as printed: 10,008,180). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 99.08% (votes for as printed: 6,550,393). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-12-03. Item 5.07 · say-on-pay result. As reported: 98.91% (votes for as printed: 604,490). View filing ↗
- Palvella Therapeutics, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Palvella Therapeutics, Inc's own proxy. As printed: 3,404,904. View filing ↗